A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patientson November 25, 2020 at 12:00 pm
Historically, patients with glioblastoma have been empirically treated with dexamethasone, even without symptoms, with many clinicians prescribing steroids for prolonged periods of time, out of a ...
- New immunotherapy shows promise against rare childhood canceron November 25, 2020 at 11:01 am
A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.
- Why immunotherapy only works for some with head and neck canceron November 24, 2020 at 6:27 am
University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't.
- Most Cost-effective to Use Immunotherapy First in Melanomaon November 24, 2020 at 5:08 am
Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.
- Global Cancer Immunotherapy Drug Discovery Outsourcing Market 2020 Size, Market Share, Key Players, Segmentation Development and Forecast by 2026on November 24, 2020 at 2:03 am
MarketsandResearch.biz has newly published research study entitled Global Cancer Immunotherapy Drug Discovery Outsourcing Market 2020 by Company, Regions, Type and Application, Forecast to 2026 that ...
- Global cancer immunotherapy market size to reach USD 117.82 billion by 2026on November 24, 2020 at 2:00 am
According to industry experts, global cancer immunotherapy market size is projected to reach USD 117.82 billion by the year 2026. Spike in the number of cases of cancer and associated deaths is ...
- Channeling the immune system for head and neck canceron November 23, 2020 at 4:00 pm
Researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't.
- New Type of Immunotherapy Developed To Fight Canceron November 23, 2020 at 4:00 pm
A new study reports on a new kind of immunotherapy that gives hope of more treatment options for cancer in the future.
- Reprogramming T cells into highly active 'super immune cells' can improve immunotherapy benefitson November 23, 2020 at 10:43 am
Immune-system T cells have been reprogrammed into regenerative stem cell-like memory (TSCM) cells that are long-lived, highly active "super immune cells" with strong antitumor activity, according to ...
via Bing News